cAMP-specific 3',5'-cyclic phosphodiesterase 4A (PDE4A1) (PDE4A1)

cAMP-specific 3',5'-cyclic phosphodiesterase 4A (PDE4A) is an enzyme responsible for the hydrolysis of cyclic adenosine monophosphate (cAMP), a vital second messenger that regulates a wide array of cellular functions. By controlling the degradation of cAMP, PDE4A plays a central role in modulating intracellular signaling pathways, particularly those involved in inflammatory and immune responses. It is highly expressed in various immune cells, including T cells, macrophages, and neutrophils, where it influences the production of pro-inflammatory cytokines. Consequently, PDE4A is a significant therapeutic target for chronic inflammatory diseases such as chronic obstructive pulmonary disease (COPD), psoriasis, and atopic dermatitis. Pharmacological inhibition of PDE4A leads to increased intracellular cAMP levels, which in turn activates protein kinase A (PKA) and suppresses the release of inflammatory mediators like TNF-alpha and various interleukins. Several PDE4 inhibitors, such as roflumilast and apremilast, are clinically approved for treating respiratory and dermatological conditions. However, the development of these drugs has been challenged by dose-limiting side effects, most notably nausea and emesis, which are believed to result from the inhibition of specific PDE4 isoforms in the central nervous system or the area postrema. Ongoing research aims to develop more selective inhibitors or localized delivery methods to maximize therapeutic efficacy while minimizing systemic toxicity.

Other names

PDE4A1PDE4A1ADPDE2PDE46Phosphodiesterase 4A

Phosphodiesterase 4 inhibitor